Ipsogen Grants Warnex Exclusive License to JAK2 Leukemia Dx in Canada | GenomeWeb
NEW YORK (GenomeWeb News) - Ipsogen said today it has granted Warnex exclusive rights to market its JAK2 leukemia diagnostic test in Canada.
 
The test is based on variations in the JAK2 gene, for which Ipsogen holds intellectual property rights. It detects certain mutations in the gene linked to myeloproliferative disorders, including myelogenous leukemia, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.